Clinical Trial Detail

NCT ID NCT02900560
Title Study of Pembrolizumab With or Without CC-486 in Patients With Platinum-resistant Ovarian Cancer
Recruitment Recruiting
Gender female
Phase Phase II
Variant Requirements no
Sponsors Translational Research in Oncology
Indications

peritoneum cancer

fallopian tube cancer

ovary epithelial cancer

Therapies

Azacitidine + Pembrolizumab

Age Groups: senior adult

No variant requirements are available.